Orphan Drugs
Catalent has extensive experience in advancing hundreds of orphan, rare, breakthrough and accelerated designation molecules employing multiple technologies.
Catalent has extensive experience in advancing hundreds of orphan, rare, breakthrough and accelerated designation molecules employing multiple technologies.
Catalent has extensive experience in advancing hundreds of orphan, rare, breakthrough and accelerated designation molecules employing multiple technologies.
Cognitive impairment can manifest itself in varying forms and degrees. While memory, learning, and/or concentrating may be challenges for many, some may experience more devastating symptoms like struggling to make decisions affecting everyday life.
At Catalent, we execute with a long-term vision for your cell therapy product. Our 5-step in-house approach translates your discoveries into manufacturable treatments at scale.
We proudly help launch countless new products while driving brand growth and market share for a diverse portfolio of global clients. With a vast offering of development capabilities, global manufacturing and regulatory services, our solutions are comprehensive. Explore our product library below to find yours.